Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Sophia Genetics SA (SOPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: SOPH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.33
1 Year Target Price $7.33
| 4 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 18.38% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 340.59M USD | Price to earnings Ratio - | 1Y Target Price 7.33 |
Price to earnings Ratio - | 1Y Target Price 7.33 | ||
Volume (30-day avg) 6 | Beta 1.11 | 52 Weeks Range 2.58 - 5.30 | Updated Date 12/5/2025 |
52 Weeks Range 2.58 - 5.30 | Updated Date 12/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.12 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -102.29% | Operating Margin (TTM) -91.78% |
Management Effectiveness
Return on Assets (TTM) -25.59% | Return on Equity (TTM) -86.09% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 315570525 | Price to Sales(TTM) 4.65 |
Enterprise Value 315570525 | Price to Sales(TTM) 4.65 | ||
Enterprise Value to Revenue 4.31 | Enterprise Value to EBITDA -0.3 | Shares Outstanding 67847058 | Shares Floating 50977565 |
Shares Outstanding 67847058 | Shares Floating 50977565 | ||
Percent Insiders 6.43 | Percent Institutions 49.57 |
Upturn AI SWOT
Sophia Genetics SA
Company Overview
History and Background
Sophia Genetics SA, founded in 2011, is a data-driven medicine company. Initially focused on genomic data analysis for clinical diagnostics, it has expanded to offer a broader suite of products and services for healthcare providers and biopharmaceutical companies.
Core Business Areas
- Data-Driven Medicine Platform: SOPHiA DDM platform analyzes genomic and multi-omic data to provide insights for diagnosis, treatment, and drug development.
- Clinical Genomics Solutions: Provides solutions for clinical laboratories, enabling them to perform genomic testing and analysis.
- Biopharma Solutions: Offers data analytics and software solutions for biopharmaceutical companies to accelerate drug discovery and development.
Leadership and Structure
The leadership team includes the CEO, CFO, and other key executives. The organizational structure is designed to support its global operations and product development efforts.
Top Products and Market Share
Key Offerings
- SOPHiA DDM Platform: A cloud-based platform for analyzing genomic and multi-omic data, offering insights for clinical diagnostics and research. Market share is estimated to be around 5-7% in the clinical genomics analysis market. Competitors include Illumina (ILMN), Roche (RHHBY), and Qiagen (QGEN). Revenue generation is not publicly available.
- Oncology Solutions: Solutions focused on genomic profiling for cancer diagnosis and treatment selection. Competitors include Foundation Medicine (acquired by Roche), Guardant Health (GH), and Exact Sciences (EXAS). Market share data is not readily available
Market Dynamics
Industry Overview
The clinical genomics market is growing rapidly, driven by advancements in sequencing technologies and increasing adoption of personalized medicine. The biopharma market for data analytics is also expanding.
Positioning
Sophia Genetics positions itself as a leader in data-driven medicine, leveraging its AI-powered platform to provide actionable insights. Its competitive advantage lies in its ability to integrate and analyze diverse types of data.
Total Addressable Market (TAM)
The TAM for clinical genomics and biopharma data analytics is estimated to be in the tens of billions of dollars. Sophia Genetics is positioned to capture a portion of this market through its platform and solutions.
Upturn SWOT Analysis
Strengths
- Proprietary AI-powered platform
- Strong focus on data privacy and security
- Established partnerships with leading hospitals and research institutions
- Global presence
Weaknesses
- Relatively small market share compared to larger competitors
- Dependence on continued technological innovation
- Requires significant investment in R&D
- Limited profitability
Opportunities
- Expansion into new therapeutic areas
- Development of new data analytics tools
- Increased adoption of personalized medicine
- Strategic partnerships with biopharmaceutical companies
Threats
- Intense competition from larger players
- Changing regulatory landscape
- Data security breaches
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- ILMN
- RHHBY
- QGEN
- GH
- EXAS
Competitive Landscape
Sophia Genetics faces intense competition from larger, more established players. Its ability to differentiate itself through its AI-powered platform and focus on data privacy is crucial.
Major Acquisitions
Not applicable
- Year: 2022
- Acquisition Price (USD millions): 0
- Strategic Rationale: No acquisitions found.
Growth Trajectory and Initiatives
Historical Growth: Sophia Genetics has experienced rapid growth in recent years, driven by the increasing adoption of its platform and solutions.
Future Projections: Analyst estimates suggest continued growth for Sophia Genetics, driven by the expanding market for clinical genomics and biopharma data analytics. Because Sophia Genetics is not a US stock this information may be difficult to obtain.
Recent Initiatives: Recent initiatives include expanding its product portfolio, strengthening its partnerships, and expanding its global presence.
Summary
Sophia Genetics SA is a data-driven medicine company with a proprietary AI platform that provides insights for diagnosis, treatment, and drug development. While it faces intense competition from larger players, it has strengths in data privacy and partnerships. The company needs to focus on growing market share and achieving profitability. Expanding into new therapeutic areas and leveraging strategic partnerships will be important for its growth trajectory. However, the viability and overall performance is difficult to calculate due to its non US nature.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- Analyst Reports (where available)
- Industry News
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sophia Genetics SA
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-07-23 | Co-Founder, CEO & Director Dr. Jurgi Camblong M.B.A., Ph.D. | ||
Sector Healthcare | Industry Health Information Services | Full time employees 423 | Website https://www.sophiagenetics.com |
Full time employees 423 | Website https://www.sophiagenetics.com | ||
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is based in Rolle, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.